PharmAust Limited (PAA) is a clinical-stage biotechnology company dedicated to developing therapeutics for both human and animal health applications. The company's primary focus is on repurposing monepantel (MPL) for the treatment of human neurodegenerative diseases and canine cancer. In addition to these core projects, PharmAust is engaged in the development of its own drug discovery intellectual property targeting various cancers, neurological disorders, and viral infections. Furthermore, the company offers specialised medicinal and synthetic chemistry services on a contract basis, catering to the specific needs of its clients. Through these diverse initiatives, PharmAust aims to advance healthcare solutions across multiple fronts.